BRIEF — New center is world's largest dedicated cell and gene manufacturing unit, says Lonza

10 April 2018

Swiss pharmaceutical and biotech ingredient supplier Lonza (VTX: LONN) is showing plenty of faith in what it calls the ‘next era in medicine’.

The company has opened the world’s largest dedicated cell-and-gene-therapy facility in Houston, Texas, a unit where 200 people will be employed by the end of the year.

Andreas Weiler, business unit head for emerging technologies at Lonza Pharma & Biotech, said: “Lonza Houston will serve as a center of excellence for cell-and-gene-therapy process development from concept through pre-clinical, clinical and commercialization, all the way to the patient.

“This facility has the potential to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases, under one roof. It will set a new standard in biopharmaceutical manufacturing and stand as one of four centers of excellence in cell and gene therapy in the only global network spanning three continents."

Companies featured in this story

More ones to watch >